文献速递心力衰竭与心肌病

利钠肽指导心衰治疗的经济与生活质量结局

Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

GUIDE-IT试验纳入894例高危射血分数降低心衰患者,比较NT-proBNP指导治疗(目标<1000 pg/ml)与常规治疗的QOL和经济结局。结果显示两种策略在KCCQ和DASI改善上无差异,生物标志物指导组总费用平均高5919美元。

要点

  • NT-proBNP指导治疗未改善QOL,KCCQ和DASI与常规治疗无差异
  • 生物标志物指导组总费用平均高5919美元,95%CI -1795至13602
  • 该策略在高危射血分数降低心衰患者中不具成本效益优势

核心结论

  • NT-proBNP指导的心衰治疗策略总费用更高,且在改善生活质量方面不优于常规治疗。

研究设计与样本

  • GUIDE-IT试验为前瞻性随机对照研究,因无效提前终止时共纳入894例高危射血分数降低心衰患者。
  • 患者随机分为NT-proBNP指导治疗组(目标NT-proBNP<1000 pg/ml)和常规治疗组。
  • QOL工具在基线及随机后3、6、12、24个月收集,合格者收集率90%至99%。
  • 成本数据收集自735例(97%)美国患者。

主要发现

  • 446例随机至NT-proBNP指导治疗,448例随机至常规治疗,基线变量均衡。
  • KCCQ和DASI在最初6个月均改善,但24个月时策略相关差异无统计学意义:DASI平均差2.0(95%CI -1.3至5.3),KCCQ平均差1.1(95%CI -3.7至5.9)。
  • 中位随访15个月,生物标志物指导组总winsorized成本平均高5919美元(95%CI -1795至13602)。

临床怎么用

  • 对于高危射血分数降低心衰患者,NT-proBNP指导治疗策略不改善生活质量且增加费用,临床决策需权衡成本效益。

局限性

  • 研究因无效提前终止,可能影响统计效能。
  • 成本数据仅来自美国735例患者(97%),经济结局的外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial prospectively compared the efficacy of an N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided heart failure treatment strategy (target NT-proBNP level <1,000 pg/ml) with optimal medical therapy alone in high-risk patients with heart failure and reduced ejection fraction. When the study was stopped for futility, 894 patients had been enrolled. OBJECTIVES: The purpose of this study was to assess treatment-related quality-of-life (QOL) and economic outcomes in the GUIDE-IT trial. METHODS: The authors prospectively collected a battery of QOL instruments at baseline and 3, 6, 12, and 24 months post-randomization (collection rates 90% to 99% of those eligible). The principal pre-specified QOL measures were the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score and the Duke Activity Status Index (DASI). Cost data were collected for 735 (97%) U.S. RESULTS: Baseline variables were well balanced in the 446 patients randomized to the NT-proBNP-guided therapy and 448 to usual care. Both the KCCQ and the DASI improved over the first 6 months, but no evidence was found for a strategy-related difference (mean difference [biomarker-guided - usual care] at 24 months of follow-up 2.0 for DASI [95% confidence interval (CI): -1.3 to 5.3] and 1.1 for KCCQ [95% CI: -3.7 to 5.9]). Total winsorized costs averaged $5,919 higher in the biomarker-guided strategy (95% CI: -$1,795, +$13,602) over 15-month median follow-up. CONCLUSIONS: A strategy of NT-proBNP-guided HF therapy had higher total costs and was not more effective than usual care in improving QOL outcomes in patients with heart failure and a reduced ejection fraction. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mark DB, Cowper PA, Anstrom KJ, et al. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. J Am Coll Cardiol. 2018. PMID: 30466512. doi:10.1016/j.jacc.2018.08.2184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。